Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
179 studies found for:    "Expanded Access" [STUDY-TYPES] | Open Studies
Show Display Options
Rank Status Study
1 Available Expanded Access Program for ONC201 to Treat Recurrent Histone H3 Mutant Glioma
Condition: Glioma
Intervention: Drug: ONC201
2 Available Single Patient, Compassionate Use of MARGETUXIMAB for the Treatment of HER2+ Metastatic Breast Cancer
Conditions: HER2-positive Breast Cancer;   Neoplasm Metastasis
Intervention:
3 Available Lorlatinib - PF-06463922
Condition:
Intervention: Drug: Lorlatinib
4 Available Inotuzumab Ozogamicin - PF-05208773
Condition:
Intervention: Drug: Inotuzumab Ozogamicin
5 Available Expanded Access for Nivolumab (Opdivo)
Condition: Pediatric Cancer
Intervention: Biological: Nivolumab
6 Available Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Biological: Elotuzumab
7 Available Compassionate Use Program For Subcutaneous (SC) Belimumab
Condition: Systemic Lupus Erythematosus
Intervention: Drug: SC belimumab 200 mg
8 Available Expanded Access to Glecaprevir/ Pibrentasvir
Condition: Hepatitis C Virus Infection
Interventions: Drug: glecaprevir;   Drug: pibrentasvir
9 Available Expanded Access to ABT-414
Condition: Cancer
Intervention: Drug: ABT-414
10 Available Expanded Treatment Protocol in Acute Lymphoblastic Leukemia
Condition: Acute Lymphoblastic Leukemia
Intervention: Genetic: CTL019
11 Available Expanded Access to Veliparib
Condition: Cancer
Intervention: Drug: Veliparib
12 Available Expanded Access to Venetoclax
Conditions: Chronic Lymphocytic Leukemia (CLL);   Multiple Myeloma;   Acute Myeloid Leukemia (AML);   Non-Hodgkin's Lymphoma
Intervention: Drug: Venetoclax
13 Available An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)
Condition: FLT3-mutated Acute Myeloid Leukemia
Intervention: Drug: Midostaurin
14 Available Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)
Condition: Metastatic Merkel Cell Carcinoma
Intervention: Drug: Avelumab
15 Available Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Condition: Ovarian Cancer
Intervention: Drug: Olaparib tablets
16 Available Omegaven for Compassionate Use in the Treatment of Parenteral Nutrition-Associated Liver Disease
Conditions: Cholestasis;   Liver Diseases
Intervention: Drug: Omegaven
17 Available Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Conditions: Acute Myeloid Leukemia (AML);   FMS-like Tyrosine Kinase-3 (FLT3) Mutations
Intervention: Drug: ASP2215
18 Available Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut
Condition: Recurrent GBM
Intervention: Biological: rindopepimut
19 Available Individual Patient Expanded Access-Glembatumumab Vedotin
Condition: Metastatic gpNMB Expressing Triple Negative Breast Cancer
Intervention: Drug: glembatumumab vedotin
20 Available Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions
Condition: Cancers With NTRK, ROS1, or ALK Gene Fusions
Intervention: Drug: Entrectinib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.